Replies to post #125158 on Innovation Pharmaceuticals Inc (IPIX)

[Amatuer17]

How many more years and where is the money?

Look at the time and money each trial is taking - except for UOB - all trials will need funding.

With CTIX - I cannot assume anything - I heard UOB talk first in 2013 - we are coming to end of 2015 and there is no sign of starting - with approx 100 patient trial - we may be looking at end of 2017

[Waverunner1]

Sox.. nice summary... I think you meant pancreatic for #2.

Planned Kevetrin trials:

1. Ovarian – single agent and in combo, phase 2, orphan status

2. Prostate – single agent, phase 2, orphan status and research grant applied

3. AML – single agent and in combo with cytarabine, phase 2, paid for by University of Bologna

4. Renal – in combo with a tyronsine kinase inhibitor, phase 2, possible Specialized Programs of Research Excellence (SPORE) grant

5. Retinoblastoma – single agent, phase 2, possible Pediatric Disease Priority Review Voucher (PPRV)

[faraifarai]

Good accurate summary...its also seriously an impressive road map...and speaks
Volumes what's happening at Dana farber

[BonelessCat]

Since some think that CTIX has to come up with a lot of money, I wanted to add to each in your list a small detail (added wording in bold):

Planned Kevetrin trials:

1. Ovarian – single agent and in combo, phase 2, orphan status
to be heavily subsidized by government and private grants

2. Pancreatic – single agent, phase 2, orphan status and research grant applied
Unmet need cancer funding available, CTIX will supply little more than the drug.

3. AML – single agent and in combo with cytarabine, phase 2, paid for entirely by University of Bologna

4. Renal – in combo with a tyronsine kinase inhibitor, phase 2, possible Specialized Programs of Research Excellence (SPORE) grant

5. Retinoblastoma – single agent, phase 2, possible Pediatric Disease Priority Review Voucher (PPRV)
Funded by Children's Cancer Research Fund among other sources including the NIH.